Last edition
News about "Zydus Cadila launches Ujvira for breast cancer tre"
Zydus Cadila launches Ujvira for breast cancer treatment
Zydus Cadila, a global innovation driven healthcare company, launched trastuzumab emtansine, the first antibody drug conjugate (ADC) biosimilar and a highly effective drug for treating both early and advanced HER2 positive breast cancer, under the brand name 'Ujvira'. HER2 positive breast cancer is considered an aggressive form and constitutes 20 to 25%
Zydus Cadila Launches Ujvira For Breast Cancer Tre | 25/05/2021 | By Darshana | 486
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy